About Eli Lilly and (NYSE:LLY)
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as immunology products to treat Alzheimer's disease. In addition, it offers oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine. Further, the company provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; and Nektar Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:LLY
CUSIP53245710
Phone317-276-2000
Debt
Debt-to-Equity Ratio0.85%
Current Ratio1.32%
Quick Ratio1.01%
Price-To-Earnings
Trailing P/E Ratio18.47
Forward P/E Ratio16.20
P/E Growth1.44
Sales & Book Value
Annual Sales$22.87 billion
Price / Sales3.79
Cash Flow$5.5364 per share
Price / Cash14.28
Book Value$10.60 per share
Price / Book7.46
Profitability
EPS (Most Recent Fiscal Year)$4.28
Net Income$-204,100,000.00
Net Margins-0.89%
Return on Equity33.01%
Return on Assets10.88%
Miscellaneous
Employees40,655
Outstanding Shares1,095,600,000
Eli Lilly and (NYSE:LLY) Frequently Asked Questions
What is Eli Lilly and's stock symbol?
Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."
How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?
Eli Lilly and declared a quarterly dividend on Monday, December 11th. Investors of record on Thursday, February 15th will be given a dividend of $0.5625 per share on Friday, March 9th. This represents a $2.25 annualized dividend and a dividend yield of 2.85%. The ex-dividend date is Wednesday, February 14th. This is an increase from Eli Lilly and's previous quarterly dividend of $0.52. View Eli Lilly and's Dividend History.
How were Eli Lilly and's earnings last quarter?
Eli Lilly and Co (NYSE:LLY) issued its earnings results on Wednesday, January, 31st. The company reported $1.14 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.08 by $0.06. The firm earned $6.16 billion during the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The firm's revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.95 earnings per share. View Eli Lilly and's Earnings History.
When is Eli Lilly and's next earnings date?
What guidance has Eli Lilly and issued on next quarter's earnings?
Eli Lilly and updated its FY18 earnings guidance on Wednesday, January, 31st. The company provided EPS guidance of $4.81-4.91 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.67. The company issued revenue guidance of $23.0-23.5 billion, compared to the consensus revenue estimate of $23.20 billion.
What price target have analysts set for LLY?
19 equities research analysts have issued twelve-month price objectives for Eli Lilly and's shares. Their predictions range from $79.00 to $115.00. On average, they anticipate Eli Lilly and's share price to reach $93.50 in the next year. View Analyst Ratings for Eli Lilly and.
What are Wall Street analysts saying about Eli Lilly and stock?
Here are some recent quotes from research analysts about Eli Lilly and stock:
- 1. According to Zacks Investment Research, "Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue in 2018. Lilly expects to launch 20 new products between 2014 and 2023, including at least two new indications/line extensions on an average every year. The decision to sell or spin-off the Animal Health segment, which underperformed in 2017, is a prudent decision in our view. However, competitive pressure on Lilly’s drugs is expected to rise this year. Meanwhile, challenges remain for the company in the form of loss of patent exclusivity for products like Cialis and the impact of generic competition for Strattera, Effient and Axiron. U.S. pricing access pressure will also remain a headwind in 2018. Nontheless, estimates have gone up ahead of the Q1 earnings release. Lilly has a positive record of earnings surprises in recent quarters." (4/11/2018)
- 2. Jefferies Group LLC analysts commented, "Date and time of first dissemination: July 17, 2017, 08:17 ET Date and time of production: July 17, 2017, 08:17 ET Target Price / Valuation Methodology: Mallinckrodt plc – MNK Our discounted cash flow (DCF) analysis leads us to a price target of $87/share for MNK shares. Our DCF considers our estimates through 2027, slowing growth through 2033 and a 10% terminal decline thereafter. In addition, we expect Mallinckrodt’s margin structure to remain somewhat consistent with our 2027 estimates. We estimate a weighted average cost of capital (WACC) of 11.4% which is in line with other companies in Mallinckrodt’s peer set due to the company’s manageable leverage and consistent cash generation potential." (7/13/2017)
Are investors shorting Eli Lilly and?
Eli Lilly and saw a drop in short interest in the month of March. As of March 29th, there was short interest totalling 10,533,801 shares, a drop of 26.5% from the March 15th total of 14,330,820 shares. Based on an average trading volume of 4,479,492 shares, the days-to-cover ratio is currently 2.4 days. Currently, 1.1% of the shares of the stock are sold short.
Who are some of Eli Lilly and's key competitors?
Some companies that are related to Eli Lilly and include Merck & Co. (MRK), AbbVie (ABBV), Novo Nordisk (NVO), Abbott Laboratories (ABT), Bayer (BAYRY), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Astellas Pharma (ALPMY) and Shiseido (SSDOY).
Who are Eli Lilly and's key executives?
Eli Lilly and's management team includes the folowing people:
- Mr. David A. Ricks, Chairman, CEO & Pres (Age 50)
- Dr. Jan M. Lundberg, Exec. VP of Science & Technology and Pres of Lilly Research Laboratories (Age 64)
- Mr. Michael J. Harrington, Sr. VP & Gen. Counsel (Age 55)
- Mr. Enrique A. Conterno, Sr. VP, Pres of Lilly Diabetes & Pres of Lilly USA (Age 51)
- Mr. Joshua L. Smiley, Sr. VP & CFO (Age 48)
Has Eli Lilly and been receiving favorable news coverage?
Media headlines about LLY stock have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Eli Lilly and earned a coverage optimism score of 0.07 on Accern's scale. They also gave media coverage about the company an impact score of 45.85 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Eli Lilly and's major shareholders?
Eli Lilly and's stock is owned by many different of retail and institutional investors. Top institutional shareholders include
PRIMECAP MANAGEMENT COMPANY
(5.00%). Company insiders that own Eli Lilly and stock include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover and Susan Mahony. View Institutional Ownership Trends for Eli Lilly and.
How do I buy shares of Eli Lilly and?
Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eli Lilly and's stock price today?
One share of LLY stock can currently be purchased for approximately $79.06.
How big of a company is Eli Lilly and?
Eli Lilly and has a market capitalization of $86.62 billion and generates $22.87 billion in revenue each year. The company earns $-204,100,000.00 in net income (profit) each year or $4.28 on an earnings per share basis. Eli Lilly and employs 40,655 workers across the globe.
How can I contact Eli Lilly and?
Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]
MarketBeat Community Rating for Eli Lilly and (LLY)
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly and and other stocks. Vote "Outperform" if you believe LLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.
Eli Lilly and (NYSE:LLY) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
19 Wall Street analysts have issued ratings and price targets for Eli Lilly and in the last 12 months. Their average twelve-month price target is $93.50, suggesting that the stock has a possible upside of 18.26%. The high price target for LLY is $115.00 and the low price target for LLY is $79.00. There are currently 8 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Hold | Hold |
| Consensus Rating Score: | 2.58 | 2.50 | 2.44 | 2.47 |
| Ratings Breakdown: | 0 Sell Rating(s)
8 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $93.50 | $93.2778 | $93.6250 | $89.8889 |
| Price Target Upside: | 18.26% upside | 21.88% upside | 9.52% upside | 3.11% upside |
Eli Lilly and (NYSE:LLY) Consensus Price Target History
Eli Lilly and (NYSE:LLY) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Eli Lilly and (NYSE:LLY) Dividend Information
Eli Lilly and pays an annual dividend of $2.25 per share, with a dividend yield of 2.85%. LLY's most recent quarterly dividend payment was Friday, March 9. The company has grown its dividend for the last 3 consecutive years and is increasing its dividend by an average of 2.00% each year. Eli Lilly and pays out 52.57% of its earnings out as a dividend.
| Most Recent Dividend: | 3/9/2018 |
| Annual Dividend: | $2.25 |
| Dividend Yield: | 2.85% |
| Dividend Growth: | 2.00% (3 Year Average) |
| Payout Ratio: | 52.57% (Trailing 12 Months of Earnings)
46.11% (Based on This Year's Estimates)
42.53% (Based on Next Year's Estimates)
|
| Track Record: | 3 Years of Consecutive Dividend Growth |
| Frequency: | Quarterly Dividend |
Eli Lilly and (NYSE:LLY) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 12/11/2017 | quarterly | $0.5625 | 2.59% | 2/14/2018 | 2/15/2018 | 3/9/2018 |
| 10/16/2017 | quarterly | $0.52 | 2.42% | 11/14/2017 | 11/15/2017 | 12/8/2017 |
| 6/19/2017 | quarterly | $0.52 | 2.51% | 8/11/2017 | 8/15/2017 | 9/8/2017 |
| 5/1/2017 | quarterly | $0.52 | 2.55% | 5/11/2017 | 5/15/2017 | 6/9/2017 |
| 12/13/2016 | quarterly | $0.52 | 3.03% | 2/13/2017 | 2/15/2017 | 3/10/2017 |
| 10/17/2016 | quarterly | $0.51 | 2.59% | 11/10/2016 | 11/15/2016 | 12/9/2016 |
| 6/20/2016 | quarterly | $0.51 | 2.81% | 8/11/2016 | 8/15/2016 | 9/9/2016 |
| 5/2/2016 | quarterly | $0.51 | 2.68% | 5/11/2016 | 5/13/2016 | 6/10/2016 |
| 12/8/2015 | quarterly | $0.51 | 2.43% | 2/10/2016 | 2/12/2016 | 3/10/2016 |
| 10/19/2015 | quarterly | $0.50 | 2.57% | 11/10/2015 | 11/13/2015 | 12/10/2015 |
| 6/15/2015 | quarterly | $0.50 | 2.42% | 8/12/2015 | 8/14/2015 | 9/10/2015 |
| 5/4/2015 | quarterly | $0.50 | 2.78% | 5/14/2015 | 5/18/2015 | 6/10/2015 |
| 12/15/2014 | quarterly | $0.50 | 2.89% | 2/11/2015 | 2/13/2015 | 3/10/2015 |
| 10/20/2014 | quarterly | $0.49 | 3.03% | 11/12/2014 | 11/14/2014 | 12/10/2014 |
| 6/16/2014 | quarterly | $0.49 | 3.31% | 8/13/2014 | 8/15/2014 | 9/10/2014 |
| 5/5/2014 | quarterly | $0.49 | 3.35% | 5/13/2014 | 5/15/2014 | 6/10/2014 |
| 12/16/2013 | quarterly | $0.49 | 3.98% | 2/12/2014 | 2/14/2014 | 3/10/2014 |
| 10/21/2013 | quarterly | $0.49 | 3.91% | 11/13/2013 | 11/15/2013 | 12/10/2013 |
| 6/18/2013 | quarterly | $0.49 | 3.82% | 8/13/2013 | 8/15/2013 | 9/10/2013 |
| 5/6/2013 | quarterly | $0.49 | 3.62% | 5/14/2013 | 5/16/2013 | 6/10/2013 |
| 12/17/2012 | quarterly | $0.49 | 3.96% | 2/13/2013 | 2/15/2013 | 3/8/2013 |
(Data available from 1/1/2013 forward)
Eli Lilly and (NYSE LLY) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.11%
Institutional Ownership Percentage: 77.66%
Eli Lilly and (NYSE LLY) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/16/2018 | Susan Mahony | SVP | Sell | 22,544 | $80.09 | $1,805,548.96 | 45,652 |  |
| 4/13/2018 | Susan Mahony | SVP | Sell | 5,165 | $80.14 | $413,923.10 | 45,652 | |
| 3/16/2018 | Joshua L Smiley | CFO | Sell | 3,000 | $79.20 | $237,600.00 | 20,029 | |
| 3/1/2018 | Donald A Zakrowski | Insider | Sell | 860 | $76.50 | $65,790.00 | | |
| 2/21/2018 | Donald A Zakrowski | Insider | Sell | 876 | $77.55 | $67,933.80 | 4,130 | |
| 2/5/2018 | Donald A Zakrowski | Insider | Sell | 900 | $81.09 | $72,981.00 | 4,130 | |
| 2/5/2018 | Jeffrey N Simmons | SVP | Sell | 9,625 | $81.12 | $780,780.00 | 152,120 | |
| 12/13/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $88.20 | $17,640,000.00 | 123,084,104 | |
| 12/11/2017 | Jeffrey N Simmons | SVP | Sell | 12,500 | $86.46 | $1,080,750.00 | 124,522 | |
| 12/4/2017 | Susan Mahony | SVP | Sell | 36,585 | $86.18 | $3,152,895.30 | 54,885 | |
| 11/10/2017 | Alfonso G Zulueta | SVP | Sell | 2,003 | $83.67 | $167,591.01 | 43,580 | |
| 10/4/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 205,000 | $86.81 | $17,796,050.00 | | |
| 9/29/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 195,000 | $85.14 | $16,602,300.00 | 123,513,247 | |
| 9/15/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 190,000 | $82.53 | $15,680,700.00 | 123,682,287 | |
| 8/31/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 180,000 | $81.06 | $14,590,800.00 | 123,865,804 | |
| 7/31/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 220,000 | $83.09 | $18,279,800.00 | 124,049,283 | |
| 6/22/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 210,000 | $84.43 | $17,730,300.00 | 124,265,804 | |
| 6/20/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 215,000 | $83.05 | $17,855,750.00 | 124,475,804 | |
| 6/12/2017 | Melissa S Barnes | Insider | Sell | 1,900 | $80.78 | $153,482.00 | 14,041 | |
| 6/9/2017 | Michael J Harrington | VP | Sell | 22,833 | $79.97 | $1,825,955.01 | 62,056 | |
| 5/4/2017 | Enrique A Conterno | SVP | Sell | 25,000 | $82.76 | $2,069,000.00 | 114,217 | |
| 3/30/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 210,000 | $84.67 | $17,780,700.00 | 124,690,804 | |
| 2/17/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 230,000 | $80.27 | $18,462,100.00 | 125,125,804 | |
| 2/6/2017 | Alfonso G Zulueta | SVP | Sell | 15,000 | $77.66 | $1,164,900.00 | 45,583 | |
| 2/3/2017 | Derica W Rice | EVP | Sell | 11,162 | $77.14 | $861,036.68 | 58,443 | |
| 2/2/2017 | Donald A Zakrowski | Insider | Sell | 2,000 | $77.52 | $155,040.00 | 886 | |
| 2/1/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 220,000 | $77.35 | $17,017,000.00 | 125,359,047 | |
| 12/16/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $72.59 | $14,518,000.00 | 125,649,408 | |
| 12/16/2016 | Melissa S Barnes | Insider | Sell | 2,093 | $82.23 | $172,107.39 | 8,169 | |
| 12/16/2016 | R David Hoover | Director | Buy | 500 | $71.85 | $35,925.00 | 33,504 | |
| 12/16/2016 | Susan Mahony | SVP | Sell | 20,242 | $72.65 | $1,470,581.30 | 67,802 | |
| 10/5/2016 | Maria A Crowe | Insider | Sell | 2,248 | $81.37 | $182,919.76 | 94,319 | |
| 8/15/2016 | Jackson P Tai | Director | Buy | 5,773 | $80.43 | $464,322.39 | 42,306 | |
| 8/12/2016 | Jackson P Tai | Director | Buy | 2,560 | $80.42 | $205,875.20 | 42,110 | |
| 7/29/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 205,000 | $82.94 | $17,002,700.00 | 125,775,804 | |
| 7/28/2016 | Donald A Zakrowski | Insider | Sell | 1,213 | $83.16 | $100,873.08 | 1,300 | |
| 7/28/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 240,000 | $82.87 | $19,888,800.00 | 126,020,570 | |
| 7/12/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 210,000 | $79.54 | $16,703,400.00 | 126,220,804 | |
| 7/7/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 225,000 | $79.14 | $17,806,500.00 | 126,442,509 | |
| 6/30/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 215,000 | $78.46 | $16,868,900.00 | 126,808,704 | |
| 6/29/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 220,000 | $77.86 | $17,129,200.00 | 126,963,785 | |
| 6/10/2016 | Melissa S Barnes | SVP | Sell | 992 | $73.77 | $73,179.84 | 10,710 | |
| 5/31/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $75.12 | $15,024,000.00 | 127,090,804 | |
| 5/12/2016 | Jackson P Tai | Director | Buy | 1,080 | $75.75 | $81,810.00 | 40,600 | |
| 5/12/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 190,000 | $75.86 | $14,413,400.00 | 127,295,910 | |
| 5/2/2016 | Donald A Zakrowski | CAO | Sell | 1,600 | $75.86 | $121,376.00 | 3,113 | |
| 4/29/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 180,000 | $75.44 | $13,579,200.00 | 127,481,005 | |
| 4/27/2016 | Alfonso G Zulueta | SVP | Sell | 12,000 | $76.27 | $915,240.00 | 45,101 | |
| 4/8/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $74.29 | $14,858,000.00 | 127,660,804 | |
| 2/5/2016 | Stephen F Fry | SVP | Sell | 15,230 | $78.87 | $1,201,190.10 | 59,690 | |
| 2/3/2016 | David A. Ricks | SVP | Sell | 5,733 | $77.66 | $445,224.78 | 79,403 | |
| 2/3/2016 | Derica W. Rice | CFO | Sell | 10,483 | $77.78 | $815,367.74 | 36,931 | |
| 2/1/2016 | Jackson P Tai | Director | Buy | 3,170 | $78.62 | $249,225.40 | 39,487 | |
| 1/29/2016 | Alfonso G Zulueta | SVP | Sell | 5,000 | $78.75 | $393,750.00 | 57,101 | |
| 12/21/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 205,000 | $86.00 | $17,630,000.00 | 127,860,804 | |
| 12/15/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 215,000 | $85.60 | $18,404,000.00 | 128,065,804 | |
| 12/9/2015 | Enrique A Conterno | VP | Sell | 25,000 | $83.88 | $2,097,000.00 | 88,131 | |
| 12/2/2015 | Lilly Endowment Inc | major shareholder | Sell | 210,000 | $85.09 | $17,868,900.00 | 128,280,804 | |
| 11/20/2015 | Lilly Endowment Inc | major shareholder | Sell | 205,000 | $84.54 | $17,330,700.00 | 128,490,804 | |
| 10/29/2015 | Lilly Endowment Inc | major shareholder | Sell | 200,000 | $82.28 | $16,456,000.00 | 128,695,804 | |
| 10/9/2015 | Lilly Endowment Inc | major shareholder | Sell | 215,000 | $85.86 | $18,459,900.00 | 128,895,804 | |
| 10/5/2015 | Lilly Endowment Inc | major shareholder | Sell | 260,000 | $86.46 | $22,479,600.00 | 129,110,804 | |
| 9/18/2015 | Lilly Endowment Inc | major shareholder | Sell | 250,000 | $89.04 | $22,260,000.00 | 129,370,804 | |
| 6/10/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 210,000 | $82.39 | $17,301,900.00 | | |
| 6/4/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $77.90 | $15,580,000.00 | | |
| 5/29/2015 | Jeffrey N Simmons | SVP | Sell | 20,000 | $78.08 | $1,561,600.00 | | |
| 5/20/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 190,000 | $73.43 | $13,951,700.00 | | |
| 5/15/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $72.83 | $14,566,000.00 | | |
| 5/8/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 195,000 | $73.28 | $14,289,600.00 | | |
| 5/1/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $73.09 | $14,618,000.00 | | |
| 3/30/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 180,000 | $73.94 | $13,309,200.00 | | |
| 3/23/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 190,000 | $76.97 | $14,624,300.00 | | |
| 3/9/2015 | Stephen F Fry | SVP | Sell | 4,000 | $69.27 | $277,080.00 | | |
| 2/4/2015 | David A Ricks | SVP | Sell | 3,147 | $69.99 | $220,258.53 | | |
| 2/4/2015 | Derica W Rice | CFO | Sell | 5,316 | $70.00 | $372,120.00 | | |
| 2/4/2015 | Jan M Lundberg | EVP | Sell | 11,085 | $70.08 | $776,836.80 | | |
| 2/3/2015 | Jan M Lundberg | EVP | Sell | 121,711 | $70.78 | $8,614,704.58 | | |
| 2/2/2015 | David A Ricks | SVP | Sell | 4,769 | $71.51 | $341,031.19 | | |
| 2/2/2015 | Derica W Rice | CFO | Sell | 10,068 | $71.84 | $723,285.12 | | |
| 12/4/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 190,000 | $71.92 | $13,664,800.00 | | |
| 12/2/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 180,000 | $70.14 | $12,625,200.00 | | |
| 11/13/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $67.73 | $13,546,000.00 | | |
| 11/5/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 180,000 | $67.00 | $12,060,000.00 | | |
| 11/4/2014 | Fionnuala M Walsh | SVP | Sell | 15,000 | $67.00 | $1,005,000.00 | | |
| 11/3/2014 | Enrique A Conterno | VP | Sell | 5,000 | $66.03 | $330,150.00 | | |
| 10/31/2014 | Fionnuala M Walsh | SVP | Sell | 7,376 | $66.58 | $491,094.08 | | |
| 10/31/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 190,000 | $66.40 | $12,616,000.00 | | |
| 10/30/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 175,000 | $66.58 | $11,651,500.00 | | |
| 10/24/2014 | Maria A Crowe | Insider | Sell | 2,750 | $65.77 | $180,867.50 | | |
| 10/6/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 210,000 | $65.63 | $13,782,300.00 | | |
| 10/1/2014 | Enrique A Conterno | VP | Sell | 5,000 | $64.86 | $324,300.00 | | |
| 9/30/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $65.07 | $13,014,000.00 | | |
| 9/10/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 210,000 | $64.77 | $13,601,700.00 | | |
| 9/3/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $63.99 | $12,798,000.00 | | |
| 9/2/2014 | Enrique A Conterno | VP | Sell | 5,000 | $63.60 | $318,000.00 | | |
| 7/29/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 250,000 | $63.03 | $15,757,500.00 | | |
| 7/28/2014 | Susan Mahony | SVP | Sell | 2,065 | $63.30 | $130,714.50 | | |
| 7/25/2014 | Enrique A Conterno | VP | Sell | 10,000 | $63.79 | $637,900.00 | | |
| 7/25/2014 | Susan Mahony | SVP | Sell | 30,000 | $63.90 | $1,917,000.00 | | |
| 7/1/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 235,000 | $62.30 | $14,640,500.00 | | |
| 6/25/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 245,000 | $62.68 | $15,356,600.00 | | |
| 6/20/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 230,000 | $61.55 | $14,156,500.00 | | |
| 6/16/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $58.73 | $11,746,000.00 | | |
| 6/5/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 190,000 | $59.53 | $11,310,700.00 | | |
| 5/21/2014 | Lilly Endowment Inc | major shareholder | Sell | 230,000 | $58.90 | $13,547,000.00 | 134,690,804 | |
| 5/12/2014 | Jackson Tai | Director | Buy | 17,157 | $59.19 | $1,015,522.83 | 32,180 | |
| 5/12/2014 | Lilly Endowment Inc | major shareholder | Sell | 210,000 | $59.33 | $12,459,300.00 | 134,920,804 | |
| 5/6/2014 | Lilly Endowment Inc | major shareholder | Sell | 190,000 | $58.79 | $11,170,100.00 | 135,130,804 | |
| 4/29/2014 | Lilly Endowment Inc | major shareholder | Sell | 200,000 | $59.43 | $11,886,000.00 | 135,320,804 | |
| 4/28/2014 | Lilly Endowment Inc | major shareholder | Sell | 150,000 | $58.64 | $8,796,000.00 | 135,520,804 | |
| 8/15/2013 | Enrique Conterno | VP | Sell | 5,000 | $53.79 | $268,950.00 | 57,177 | |
| 7/29/2013 | Jacques Tapiero | SVP | Sell | 7,500 | $53.74 | $403,050.00 | | |
| 7/15/2013 | Enrique A Conterno | VP | Sell | 5,000 | $51.43 | $257,150.00 | | |
| 6/17/2013 | Enrique A Conterno | VP | Sell | 5,000 | $52.45 | $262,250.00 | | |
| 5/15/2013 | Enrique A Conterno | VP | Sell | 5,000 | $56.15 | $280,750.00 | | |
| 5/10/2013 | Jeffrey N Simmons | SVP | Sell | 10,000 | $54.49 | $544,900.00 | | |
| 3/26/2013 | Susan Mahony | SVP | Sell | 5,000 | $56.00 | $280,000.00 | | |
(Data available from 1/1/2013 forward)
Eli Lilly and (NYSE LLY) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Big Week Ahead for Eli Lilly: Here's What to Look For
finance.yahoo.com - April 21 at 5:05 PM |
| Big Week Ahead for Eli Lilly: Here's What to Look For
finance.yahoo.com - April 21 at 5:05 PM |
 | Eli Lilly & Co. (LLY) Reports Additional Top-Line Results from CYRAMZA Phase 3 RANGE Study
www.streetinsider.com - April 21 at 8:33 AM |
| Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
finance.yahoo.com - April 20 at 5:09 PM |
| Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer
finance.yahoo.com - April 20 at 5:09 PM |
| Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
finance.yahoo.com - April 20 at 5:09 PM |
| Lilly to Present Phase 3 Data at AAN 2018 Reinforcing Commitment to New, Innovative Therapies in Migraine
finance.yahoo.com - April 20 at 5:09 PM |
 | Eli Lilly and (LLY) Rating Reiterated by Citigroup
www.americanbankingnews.com - April 19 at 10:46 PM |
| Eli Lilly and (LLY) Price Target Raised to $90.00
www.americanbankingnews.com - April 19 at 10:46 PM |
 | Eli Lilly, Incyte shares fall after FDA cites issues with rheumatoid arthritis drug
www.marketwatch.com - April 19 at 5:23 PM |
 | Investors mull Gilead's filgotinib in wake of Eli Lilly's/Incyte's baricitinib
seekingalpha.com - April 19 at 5:23 PM |
| Eli Lilly's Blockbuster Resurrection Story Has Holes
finance.yahoo.com - April 19 at 5:23 PM |
| Eli Lilly and Incyte down premarket ahead on bearish outlook on Ad Com review for arthritis med baricitinib
seekingalpha.com - April 19 at 8:33 AM |
 | FDA Panel on Lilly’s Arthritis Drug Is the Next Big Test for Biotech Investors
www.bloomberg.com - April 18 at 5:31 PM |
| Eli Lilly and Co (LLY) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 18 at 5:30 PM |
| Eli Lilly and's (LLY) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - April 18 at 9:53 AM |
| See what the IHS Markit Score report has to say about Eli Lilly And Co.
finance.yahoo.com - April 18 at 8:33 AM |
| Eli Lilly and Co (LLY) Forecasted to Earn Q1 2018 Earnings of $1.14 Per Share
www.americanbankingnews.com - April 18 at 7:54 AM |
| 2 Diabetes Growth Stocks And 1 Moonshot To Hold Through 2025
seekingalpha.com - April 17 at 5:41 PM |
| Insider Selling: Eli Lilly and Co (LLY) SVP Sells 5,165 Shares of Stock
www.americanbankingnews.com - April 17 at 4:23 PM |
| Eli Lilly and Co (LLY) SVP Sells $1,805,548.96 in Stock
www.americanbankingnews.com - April 17 at 4:23 PM |
| Eli Lilly and Co (LLY) Short Interest Down 26.5% in March
www.americanbankingnews.com - April 17 at 1:59 AM |
| Eli Lilly and (LLY) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - April 17 at 1:20 AM |
 | Quotidian Technical Highlights on Selected Drug Makers Stocks -- AbbVie, Biostar Pharma, Bristol-Myers Squibb, and ...
www.prnewswire.com - April 16 at 8:31 AM |
| Eli Lilly & Co. (LLY) & Boehringer Ingelheim Announces Academic Collaboration with Oxford University for Jardiance ...
www.streetinsider.com - April 16 at 8:31 AM |
| Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease
www.prnewswire.com - April 16 at 8:06 AM |
| Zacks: Analysts Anticipate Eli Lilly and Co (LLY) Will Announce Quarterly Sales of $5.50 Billion
www.americanbankingnews.com - April 16 at 3:44 AM |
| Jefferies Group Comments on Eli Lilly and Co's Q1 2018 Earnings (LLY)
www.americanbankingnews.com - April 16 at 1:19 AM |
| Leerink Swann Lowers Eli Lilly and (LLY) to Market Perform
www.americanbankingnews.com - April 15 at 9:29 PM |
| Eli Lilly and (LLY) Downgraded by UBS to "Hold"
www.americanbankingnews.com - April 15 at 8:22 PM |
| Eli Lilly and (LLY) Rating Reiterated by Berenberg Bank
www.americanbankingnews.com - April 15 at 12:01 PM |
| Zacks: Brokerages Anticipate Eli Lilly and Co (LLY) Will Announce Earnings of $1.13 Per Share
www.americanbankingnews.com - April 14 at 11:28 AM |
| UPDATE: BMO Capital Upgrades Eli Lilly (LLY) to Market Perform Citing More Balanced Risk/Reward
www.streetinsider.com - April 13 at 5:16 PM |
| Eli Lilly's stock rallies after BMO raises rating, price target
finance.yahoo.com - April 13 at 5:16 PM |
| BMO's Bearish Stance On Eli Lilly Comes To An End
finance.yahoo.com - April 13 at 5:16 PM |
| Eli Lilly and (LLY) Lifted to "Market Perform" at BMO Capital Markets
www.americanbankingnews.com - April 13 at 10:37 AM |
| Jefferies Group Analysts Give Eli Lilly and (LLY) a $90.00 Price Target
www.americanbankingnews.com - April 13 at 10:13 AM |
| Global Clinical Trials Market Overview 2017-2026: Roche Group., Eli Lilly and Company
www.marketwatch.com - April 13 at 8:43 AM |
| Global Auto-Injectors Market Overview 2017-2026: Antares Pharma Inc., Bayer AG, Eli Lilly and Company
www.marketwatch.com - April 13 at 8:43 AM |
| Better Buy: AbbVie Inc. vs. Eli Lilly
finance.yahoo.com - April 13 at 8:43 AM |
| Eli Lilly and (LLY) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 11 at 7:56 AM |
| AbbVie's RA Candidate Meets Primary Endpoints in Phase III
finance.yahoo.com - April 10 at 5:16 PM |
 | The search for new Alzheimer's treatments just faced another setback — and now everything hinges on an approach that's already run into trouble
www.businessinsider.com - April 10 at 8:49 AM |
| How Bristol-Myers Squibb Stock Performed in 1Q18
finance.yahoo.com - April 10 at 8:49 AM |
| Eli Lilly and (LLY) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 9 at 1:55 PM |
| SunTrust Banks Brokers Increase Earnings Estimates for Eli Lilly and Co (LLY)
www.americanbankingnews.com - April 9 at 2:32 AM |
| Eli Lilly and (LLY) Rating Reiterated by Cowen
www.americanbankingnews.com - April 7 at 11:00 PM |
| Better Buy: Eli Lilly and Co. vs. GlaxoSmithKline
finance.yahoo.com - April 7 at 4:18 PM |
 | Active-Investors: Wired News - Eli Lilly's Phase-3 REACH-2 Study of CYRAMZA(R) Met its Primary Endpoint of Overall Survival
www.finanznachrichten.de - April 6 at 8:47 AM |
| Wired News – Eli Lilly's Phase-3 REACH-2 Study of CYRAMZA(R) Met its Primary Endpoint of Overall Survival
finance.yahoo.com - April 6 at 8:47 AM |
Eli Lilly and (NYSE:LLY) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Eli Lilly and (NYSE:LLY) Income Statement, Balance Sheet and Cash Flow Statement
Eli Lilly and (NYSE LLY) Stock Chart for Sunday, April, 22, 2018
Loading chart…
